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TO OUR READERS 
Appropriately, the MCV OUARTERL Y be-
gins a new volume for 1 979 with a new format. 
Although the basic alterations of size and mail-
ing method were dictated by a desire to reduce 
rising publication costs, we carried the impetus 
to change even further with the introduction of a 
new typeface and layout For example, the 
table of contents will now be published on the 
outside back cover for easy reference. These 
and other modifications have streamlined our 
appearance and provided a few more pages for 
papers-papers which we hope will continue to 
be of high interest to practicing physicians as 
well as students of medicine. 
INTRODUCTION 
The McGuire Lecture Series honors Stuart 
McGuire, M.D , L.LD. who served the Medical 
College of Virginia from 1913 to 1948 as Pro-
fessor of Surgery, Dean, President, and Chair-
man of the Board of Visitors. His relentless dedi-
cation was a primary force in moving MCV into 
the national mainstream of medical education. 
The 50th McGuire Lecture Series pre-
sented current reviews in clinical cardiology and 
hypertension for practicing physicians and med-
ical students. Speakers were members of the 
faculty of the Divisions of Cardiology and Car-
diovascular Surgery at the Medical College of 
Virginia, and Dean T. Mason , M.D., Chief of the 
Cardiovascular Section at the University of Cali-
fornia at Davis. Dr. Mason , who is the out-
standing authority on the management of con-
gestive heart failure by reduction of the load 
against which the heart must pump, was the 
McGuire Lecturer. 
The audience attending this lecture series 
came from several states and represented vari-
ous medical disciplines They entered freely into 
the discussion and thus contributed greatly to 
the value of the presentations We offer thanks 
to them , to the lecturers whose talks are pre-
sented in this issue of the MCV OUARTERL Y, to 
the Department of Continuing Medical Educa-
tion whose planning for this symposium was 
both thorough and efficient , and especially to 
Dr. Mason , who gave a magnificent McGuire 
Lecture. 
DAVID W. RICHARDSON , M.D. 
Chairman, Oivison o f Cardiology 
The Role of the Exercise Stress 
Test in the Adult 
DONALD W. ROMHIL T, M D. 
From the Division of Cardiology, Medical College of Virginia , Health Sciences Division of Virginia 
Commonwealth University , Richmond, Virginia 
The use , limitations, and value of the exer-
cise stress test have been under debate in the 
recent cardiology literature . 1- 5 The purpose of 
th is discussion is to examine the current role of 
the stress test. 
Procedure 
Common reasons for obtaining a stress 
test are: 
1 . Chest pain evaluation; 
2. Screening for coronary heart disease 
in asymptomatic persons; 
3. Post-myocardial infarction , including 
rehabilitation ; 
4. Angina pectoris evaluation; 
5. Arrhythmia evaluation--complemen-
tary to Holter monitoring ; this is less 
sensitive than the 24-hour Holter mon-
itor but will detect arrhythmias not 
present on the Holter recording ; 
6. Functional capacity evaluation (also 
used in valvular heart disease and 
other types of heart disease); 
7. Evaluation of therapy (coronary by-
pass surgery, antiarrhythmic agents, 
propranolol, rehabilitation programs). 
Patients with the following problems are usually 
not exercised : 
1 . Recent myocardial infarction (although 
the test can be done at three weeks to 
a h'eart rate of 1 30 or symptoms , or at 
two to three months to 85% of pre-
dicted maximal heart rate): 
Correspondence and reprint requests to Dr . Donald 
W. Romhilt , Box 51, Medical College ot Virginia , Richmond 
VA 23298. ' 
2. Acute myocarditis or pericarditis ; 
3. Acute coronary insufficiency or un-
stable angina pectoris (since an exer-
cise test can precipitate a myocardial 
infarction , it is preferable to wait two to 
three weeks until the patients 's condi-
tion is stable); 
4. Rapid ventricular or atrial arrhythmias; 
5. Second- or third-degree heart block; 
6. Congestive heart failure ; 
7. Acutely ill patients (infections, hyper-
thyroidism) ; 
8. Severe symptomatic aortic stenosis. 
For practical purposes, ST-segment 
changes cannot be interpreted in the presence 
of digitalis, left bundle-branch block , left ven-
tricular hypertrophy with the ST-T wave 
changes of the left ventricular stra'in pattern on 
the resting ECG , or the Wolff-Parkinson-White 
syndrome. The stress test is more difficult to in-
terpret in patients with resting ST-T wave 
changes, particularly in women . If possible , car-
diac medications should be discontinued prior 
to the test. 
There are many different protocols for ex-
ercise tests. I prefer the submaximal graded 
treadmill exercise test , using the Bruce pro-
tocol. 6 This is a continuous test with incremental 
increases in the elevation and speed of the 
treadmill every three minutes (Table 1 ). Patients 
are exercised to a target heart rate which is 
90% of their age-predicted maximum heart rate 
(Table 2) The predicted maximum heart rate for 
untrained individuals is 205 - .41 (age, years) 
beats/minute and for athletically trained per-
sons is 1 98 - .41 (age, years) 7 Post-myo-
cardial infarction patients are exercised to 85% 
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TABLE 1 
Bruce Protocol 
STAGE SPEED (mph) GRADE(%) 
1 1.7 10 
2 2.5 12 
3 3 .4 14 
4 4 2 16 
5 5 0 18 
6 5.5 20 
7 6 .0 22 
of their age-predicted maximum heart rate. 
Thus , the stress test requires a considerable 
amount of effort on the part of the patient. 
The major reasons for stopping an exer-
cise test are as follows: 
1. Target heart rate achieved; 
2. Chest pain typical of angina pectoris; 
3. Arrhythmias such as 
a. prem ature ventricu lar con-
tractions-pairs, bigeminy , R on 
T, or increasing frequency , 
b . ventricular tachycardia (~3 
PVCs) , 
c. atrial fibrillation , flutter , tachy-
cardia , 
d. heart block-second- or third-de-
gree ; 
4. Marked hypertension (>250 mm Hg 
systolic) ; 
5. Hypotension with continuing exercise 
(>1 0 mm Hg fa ll in systolic pres-
sure) ; 
6. Fatigue , weakness , dyspnea; 
7. Cerebral symptoms such as dizzi-
ness ; 
8. Intermittent claudication ; 
9 . Decrease in heart rate with contin-
uing exercise ; 
1 0 . Marked ST-segment depression; 
11 . General appearance-pale , vaso-
constricted appearance . 
Interpretation 
The interpretation of the exercise test is 
based on ST-segment changes , although there 
are other factors to be considered. The exercise 
test is considered positive when there is 1 mm 
of add itional ST-segment depression which is 
horizontal or down-sloping for at least . 08 sec-
onds (Fig 1) or 1 mm of ST-segment elevation in 
an ECG lead without 0 waves. When ST-seg-
ment elevation occurs with exercise in a lead 
without O waves, there is usually a very critical 
narrowing of at least one of the coronary arter-
ies. The following are other findings which 
should be considered in the interpretation of the 
exercise test: 
1 . Chest pain typical of angina pectoris 
during the test should be recorded in 
the interpretation . 
2. An increase in R wave height with ex-
ercise in the left precordial leads is ab-
normal. 8 Patients without coronary 
heart disease decrease their systo lic 
and diastol ic vo lume progressively 
with exerc ise wh ich results in a de-
crease in R wave height ; the ischemic 
ventric le is unable to decrease its vol-
ume and R wave height increases. 
3. Inverted U waves in the absence of 
antiarrhythmic drugs or left ventricular 
hypertrophy ; in c idence is probably 
small. 
4 . Hypotensive response to exerc ise: A 
fall in systo li c blood pressure of 1 0 
mm Hg or more is abnormal ; other 
etiologies of severe heart disease and 
vasovaga l responses must be ex-
cluded. 
5. Ventricular arrhythm ias: Premature 
ventricular contractions at low heart 
rates (below 1 30) with exercise in pa-
tients who do not have PVCs at rest; 
TABLE 2 
Maximal Heart Rates (MHR) 
AGE (yea rs) 
20 25 30 35 40 4 5 50 5 5 60 65 70 75 80 
PHYSICALLY TRAINED 
MHR 197 195 193 19 1 189 187 184 182 180 178 176 174 172 
90% MHR 177 175 173 172 170 168 166 164 162 160 158 157 155 
85% MHR 167 166 164 162 161 160 156 155 153 151 150 148 146 
PHYSICALLY UNTRAINED 
MHR 190 188 186 184 182 180 177 175 173 171 169 167 165 
90% MHR 171 169 167 166 164 162 159 158 156 154 152 150 149 
85% MHR 161 160 158 156 155 153 150 149 147 145 144 142 140 
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these are probably not specific for cor-
onary heart disease. 
6. Development of a pansystolic murmur 
of mitral regurgitation . 
The interpretation of the exerci se test 
must be assessed in the clinical setting in which 
it occurs. The largest amount of information is 
available in patients with chest pain. A few 
years ago we evaluated the sensitivity and 
specific ity of the exercise test in 1 24 patients 
with chest pain undergoing coronary arteri-
ography. 9 The criterion for a positive exercise 
test was 1 mm of additional ST-segment de-
pression (or elevation) which was horizontal or 
down-sloping for . 08 second. Sixty-five patients 
had greater than a 50% narrowing of one coro-
nary artery; 49 (75%) of these had a positive 
exercise test ; thus there were 25% false-nega-
tives . Fifty-nine patients had less than a 50% 
narrowing in any coronary artery; 4 (7%) had a 
positive exercise test and were considered to be 
false-positives. This sensitivity of 7 5% and 
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specificity of 93% is comparable to eight other 
studies 10- 11 where sensitivity ranged from 54% 
to 80% and specificity from 88% to 97% . The 
sensitivity of the exercise test will be higher in 
patients with three-vessel disease than in pa-
tients with single-vessel disease. The use of 
slowly up-sloping ST segments with ST-segment 
depression greater than or equal to 1 . 5 mm at 
80 msec after the J point increased the sensitiv-
ity in one study from 64% to 76% but de-
creased specificity from 93% to 82%. 17 It is im-
portant to reali ze that most false-negative 
calculations include only those patients who 
reach their target heart rate . 
In general , patients with more severe cor-
onary artery disease will have an exercise test 
which is positive at lower heart rates and during. 
the early stages of the test . We compared the 
maximum heart rate achieved during an exer-
cise test with the severity of coronary artery dis-
ease on angiography 18 in 40 patients with a 
positive exercise test. 8 There was a significant 
Exercise 
Fig 1-Example ot positive exercise test. In the exercise tracing there is more than 1 mm ot ST-segment depression which is 
horizontal and persists tor more than .08 seconds. 
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inverse correlation (p >.001, r = -0.62) be-
tween the severity of coronary artery disease 
and the maximum heart rate achieved (Fig 2). In 
a recent study patients who had a positive exer-
cise test in stage I or II had : (1) greater than a 
60% chance of having three-vessel disease, (2) 
greater than a 25% chance of having main left 
coronary artery disease, (3) greater than a 97% 
chance of having coronary heart disease, and 
( 4) nonsurgical patients had a survival rate of 
85% at one year and 63% at four years. 19 
In post-myocardial infarct ion patients the 
diagnosis of coronary artery disease is estab-
lished , but the exercise test may provide useful 
information . A recent study has shown that an 
exercise test to symptoms, or a heart rate of 
130, is safe at three weeks post-infarction. 2 0 
Patients with a positive test based on ST-seg-
ment depression have a significantly higher 
incidence of cardiac events during the next 
eighteen months. At two or three months post-
infarction patients who have additional ST-seg-
ment elevation in leads with a 0 wave have a 
high incidence of either a ventricular aneurysm 
14 
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MAXIMUM HEART RATE 
Fig 2-Regression analysis of inverse linear relationship be-
tween maximum heart rate at the conclusion of exercise 
and severity of coronary artery disease. The severity score 
is based on the findings of Friesinger and co-workers. 18 
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or a large infarction. 21 22 Post-infarction pa-
tients22 with a positive exercise test based on 
ST-segment depression are likely to have mul-
tiple-vessel disease (8 7%) compared to patients 
with a negative test who are likely to have 
single-vessel disease (62%). 
The assessment of the meaning of a posi-
tive exercise test is most difficult in the asympto-
matic patient . It is difficult to determine the sen-
sitivity and specificity in this population because 
coronary arteriograms are not routinely done. In 
selected populations where they have been 
done the incidence of false-positives has 
ranged from 36% to 69%23-25 and were lowest 
in the least selected population . The per-
sistence of ST-segment depression for two min-
utes after termination of exercise may improve 
the specificity in asymptomatic patients. 26 De-
spite the large percentage of false-positives , 
there is a significant increase in cardiac event 
rate (myocardial infarction and sudden death) in 
asymptomatic subjects with a positive test com-
pared to those with a negative test. 21 Also, it 
should be recognized that the significance of a 
positive exercise test is entirely different in an 
asymptomatic young woman who has 1 mm of 
horizontal ST-segment depression at the end of 
the tenth minute of exercise which lasts for 20 
or 30 seconds compared to a middle-aged man 
with 2 or 3 mm of horizontal ST-segment de-
pression in the fourth minute of exercise which 
persists for several minutes. 
In summary, the exercise stress test can 
provide useful information in the diagnosis and 
prognosis of patients with heart disease or sus-
pected heart disease when it is interpreted with 
the knowledge of the clinical findings. 
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Thallium 201 Myocardial Imaging 
MICHAEL J. COWLEY, M.D. 
Assistant Professor of Medicine, Cardiovascular Disease, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
In recent years technological advance-
ments in nuclear medicine have resulted in in-
creasing interest in the use of radioisotope tech-
niques in the evaluation of card iac disease , and 
cardiovascular nuclear medicine has developed 
into a useful noninvasive tool in clinical cardiol-
ogy. Myocardial infarct imag ing with tech-
netium-99m pyrophosphate has been demon-
strated to be a reliable method in the diagnosis 
of suspected myocardial infarction . 1 2 Radio-
isotope card iac flow studies are useful in the di-
agnosis and follow-up of congen ital heart dis-
ease ; 3 and gated cardiac blood pool imaging is 
emerging as an important technique in the eval-
uation of left vent ri cu lar function and ejection 
fraction. 4 5 One of the more promising recent 
appli cat ions of nuclear medicine in cardiology 
has been the development of myocardial per-
fusion imaging in the evaluation of coronary ar-
tery disease. Thallium 201 is the major radio-
isotope emp loyed in myocardial perfusion 
imaging and this report will review its basic 
properties and its use in the diagnosis of is-
chemic heart disease. 
Myocardial Perfusion Imaging 
Myocardial perfusion imaging (MPI) refers 
to the use of certain radioisotope tracers which 
are rapidly and selectively concentrated in the 
heart . It is based on the principle that myo-
cardial uptake of these isotopes occurs primar-
ily as a function of myocardial blood flow and 
function . The resultant pattern of activity pro-
vides an assessment of regional myocardial 
blood flow by comparing the amount and distri-
Correspondence and reprint requests to Dr. Michael 
J Cowley, Box 95, Medical College of Virginia, Richmond, 
VA 23298. 
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bution of activity in different areas of the heart . 
Regions of normal and abnormal myocardium 
are thereby distinguished by the presence and 
location of differences in myocardial radio-
activity. Of the various radioisotopes which 
have been used for MPI , thallium 201 pos-
sesses the best radiation characteristics (Table 
1) and has been the most widely investigated. 
Thallium 201 is an analogue of potassium and 
exhibits similar biologic and physical proper-
ties6; it is a monovalent cation with a half-life of 
73 hours and is readily concentrated in the 
myocardium by an active transport process 
involving membrane sodium-potassium 
adenosinetriphosphatase (ATPase). Thallium 
201 emits low-energy photons which permit 
imaging with a scintillation camera and provide 
for high spatial resolution ; it has a high myo-
cardial extraction ratio , with 80% to 90% of an 
injected dose concentrated in the heart within 
the first few minutes , and exhibits a high myo-
cardial-to-background ratio which contributes to 
improved image resolution. These features al-
low for prompt imaging following injection and a 
low patient radiation dose. 
Myocard ial activity with MPI is dependent 
on both the initial distribution of the radioisotope 
and its subsequent redistribution with time. The 
distribution phase is most important with early 
imaging and is determined both by isotope de-
livery to different regions of the heart and by 
myocardial extraction. Radioisotope delivery is 
a flow-dependent process and has been shown 
experimentally to be proportional to regional 
myocardial blood flow. 7 Myocardial extraction 
of thallium 201 is a cell-dependent process re-
quiring functioning myocardial cells. Distribution 
of thallium 201 occurs rapidly into normal areas 
of myocardium but may be significantly delayed 
to zones of diminished coronary blood flow and 
may be absent in regions of abnormal function 
which are unable to concentrate the isotope. 
Redistribution is homogeneous in normal hearts 
but is heterogeneous in zones of significantly di-
minished flow or function. Washout of thallium 
201 begins early from normal areas and is de-
tectable at one hour; while this is in process 
from normal areas, continuing uptake is often 
occurring into flow-limited areas which exhibit 
initially delayed myocardial uptake. These re-
gions will eventually show normalization of ac-
tivity if viable myocardium is present , and redis-
tribution is usually complete within one to four 
hours. 8 Areas of persistently diminished activity 
generally indicate impaired myocardial function 
and represent myocardial infarction. 
Technique 
Thallium 201 in a dose of 1 to 2 mCi is 
administered intravenously either at rest or at 
the peak of exercise when MPI is used in con-
junction with treadmill exercise testing . Myo-
cardial images are recorded using a stationary 
or portable scintillation camera. Early images 
are obtained 1 0 to 1 5 minutes after injection 
and reflect the status of myocardial perfusion at 
the time of injection. If the early image is abnor-
mal , delayed imaging three to four hours later is 
performed to look for redistribution into is-
chemic areas. Multiple views are obtained to as-
sess the different areas of myocardium with 
minimal superimposition and overlap. Inter-
pretation is done by comparison of regional 
myocardial activity; a normal image will demon-
strate a relatively homogeneous distribution of 
radioisotope within the left ventricle (Figs 1 and 
2), and an abnormality is represented by dimin-
ished activity, appearing as a "cold" .area (Fig 
3) A defect which is persistent on late images 
indicates damaged myocardium or scar (Fig 4), 
and a transient defect which is present on early 
images but has resolved with delayed imaging 
represents an area of reversible ischemia (Fig 
5). Difficulty with interpretation may occur when 
only small differences in regional activity are 
present, but this may be improved by use of 
computer processing techniques. 
Myocardial Infarction 
One area of clinical application of thallium 
201 MPI is in the diagnosis of myocardial in-
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Fig 1- Normal thallium 2 01 MPI in the anterior (ANT), left 
anterior oblique (LAO), and left lateral (LLA TL) projections 
Myocardial uptake in the left ventric le is intense and homo-
geneous. The diagram to the right of each image indicates 
the ventricular and coronary anatomy in each projection. 
AW = anterior wall ; FW = free wall ; IVS = interventricular 
septum; IW = left ventricular inferior wall; LAD = left ante-
rior descending artery distribution; LC = region of left c ir-
cumflex artery ; PLW = posterior lateral wall ; RCA = right 
coronary artery distribution. 
farction. Several investigators have demon-
strated a high sensitivity for thallium 201 in the 
detection of acute myocardial infarction. 9 - 1 1 In 
these studies sensitivity was greater than 95% 
in patients with transmural infarction and from 
80% to 85% for nontransmural infarction. Sen-
sitivity is unaffected by location of infarction but 
is dependent on infarct size, with decreased 
TABLE 1 
Myocardial Perfusion Imaging 
Radionuc lides K-43 , Rb-81 , Cs-1 29, Tl-201 
• Analogues of K + : physical and biologic 
·Tl-20 1 - best radiation characteristics 
• tYi - 73 hours 
• low-energy emission characteristics 
• high myocardial extraction ratio (80%) 
• high myocardial-to-background ratio 
• low patient radiation dose (07 rad / mCi) 
• usual dose = 1 to 2 mCi 
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GXT 
c 
Fig 2-Normal thallium 201 study with exercise (GXT) in the anterior (left), left anterior oblique (center) , and left lateral ( right) 
views. Activity in the left ventricle is homogeneous and intense, and there is activity seen in the right ventricle in the left and 
center panels. Right ventricular activity is often detectable with exercise. This patient had typical angina pectoris with normal 
coronary arteries on angiography and a false-positive exercise electrocardiogram. 
THALLIUM - 201 MYOCARDIAL SCINTIGRAMS 
ANT L . A . O L.L . 
EE 
Fig 3-Abnormal thallium 201 rest image in the anterior (ANT), left anterior oblique (LAO), and left lateral (LL) pro1ections in a 
patient with acute anterior myocardial infarction . A large area of diminished activity is evident in the anterior and apical regions 
of the left ventricle in each projection. 
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Fig 4-Thallium 201 exercise MPI with early (left) and delayed (right) images in the left anterior oblique projection in a patient 
with atypical chest pain and history of previous myocardial infarction. The immediate image shows an anteroseptal defect and 
the delayed image recorded four hours later shows no redistribution into this area, indicating a fixed or irreversible defect from 
previous myocardial infarction. 
Fig 5-Thallium 201 exercise (GXT) study in a patient with angina pectoris. The image at left was recorded immediately follow-
ing completion of exercise and demonstrates a large area of markedly diminished activity in the anteroseptal region of the left 
ventricle. The image at right was obtained four hours later and shows redistribution of activity into the anteroseptal reg ion with 
normalization of activity, indicating reversible, exercised-induced ischemia. 
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Fig 6-Serial thallium 201 MPI in anterior (ANT), left ante-
rior oblique (LAO), and left lateral (LL) projections in a pa-
tient with posterior wall infarction. Arrows indicate a defect 
at 4.5 hours after onset of chest pain This defect is dimin-
ished on the repeated studies 24 hours and 8 days later, 
especially in the LAO view. 
sensitivity in small infarctions. Sensitivity is also 
dependent upon time, with rare false-negative 
studies being obtained in the first 6 hours after 
infarction and an increased incidence of false-
negative results observed after 24 hours. 9 In ad-
dition , serial thallium 201 studies in the same 
patient have also demonstrated that the size of 
the defect often changes with time, usually 
being largest during the first 24 hours and be-
coming smaller and more stable in size after 48 
hours (Fig 6). 9 This observation probably in-
dicates detection of zones of reversible peri-in-
farction ischemia in addition to acute infarction 
in its early course which resolves with time, 
TABLE 2 
Exercise Thallium Imaging 
CLINICAL APPLICATIONS 
Improved sensitivity over exercise testing alone 
Clari fication of equivocal stress test 
Diagnosis when stress test uninterpretable 
Conduction defect (LBBB) 
Left ventricular hypertrophy 
Resting ST-segment abnormality 
Digitalis effect 
Identification of false-positive stress test 
Evaluation of coronary bypass graft function 
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leaving only the residual area of infarction ap-
parent on subsequent images. The size of the 
defect with thallium 201 MPI also correlates 
well with the size of the infarct as determined by 
serum enzyme techniques, 12 pathological anal-
ysis, 11 and quantitative left ventricular angiogra-
phy. 13 However, application of thallium 201 MPI 
in suspected myocardial infarction is limited in 
patients with previous myocardial infarction be-
cause of the isotope 's inability to distinguish 
new infarction from old infarctions or ventricular 
aneurysm. There is also reduced specificity with 
small infarctions (as with serum enzymes and 
electrocardiographic diagnosis) because of the 
limits of resolution of the technique. 14 In addi-
tion , MPI at rest may be abnormal with early 
imaging in some patients having unstable an-
LAO LLAT L 
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STR ESS 
I _ 
SCA - 90% LAD t ern 
Fig ?-False-negative stress electrocardiogram. Resting 
(top) and stress (bottom) electrocardiogram and thallium 
201 MPI in the anterior (ANT), left anterior oblique (LAO), 
and left lateral (LLATL) projections in a patient whose coro-
nary angiograms (SCA) demonstrated significant left ante-
rior descending coronary artery stenosis. The resting scinti-
gram reveals homogeneous radioactivity. With stress, the 
interventricular septum and anterior left ventricular walls (ar-
rows), the regions supplied by the stenotic vessel, are 
barely visable. The electrocardiogram shows no ischemic 
change on exercise. 
LVH 
SCA - NORMAL 
REST 
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Fig 8-Normal thallium 201 MPI and equivocal stress elec-
trocardiogram in a patient with normal coronary arteries on 
ang iography (SCA) Resting (top) and stress (bottom) elec-
troca rdiogram and stress imag ing in the anterior (left) , left 
anterior oblique (center) and left lateral ( right) projections in 
a patient with troublesome atypical chest pain and a history 
of hypertension. The fu ll resting electrocardiogram revea led 
left ventricular hypertrophy (L VH) The monitored lead 
showed ST-segment depression that deepened with stress 
and was difficu lt to interpret in view of the depression at 
rest. The perfusion image was normal and clari fied the 
stress electrocardiogram 
gina witho'ut infarction owing to severely re-
duced flow , 15 but this can usually be clarified if 
delayed images are also obtained. Thallium 
201 studies may also be abnormal in certain 
forms of noncoronary heart disease, particularly 
cardiomyopathy . 16 For these reasons , thallium 
201 MPI appears to have limited general useful-
ness for the diagnosis of acute infarction but 
can be of value to confirm infarction in situa-
tions when standard criteria are not helpful. It 
has been useful in screening patients for coro-
nary care unit admission. 9 
Exercise Myocardial Imaging 
Thallium 201 MPI has its greatest appli-
cation when used in combination with treadmill 
exercise testing for the evaluation of chest pain 
and transient myocardial ischemia , 1 7 - 2 0 and it 
provides advantages over exercise testing alone 
ANT LAO LLATL 
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Fig 9-False-positive stress elect rocard iogram. Stress thal-
lium 20 1 MPI in the anterior (ANT), left anterior oblique 
(LAO), and left lateral (LLA TL) pro1ect1ons (top) and the rest-
ing and stress electrocardiograms (bottom) in a patient with 
normal coronary arteries on angiography (SCA), Rad io-
nuc lid e dist ributi on was norma l , but the st ress elec-
trocardiogram showed distinct and sign ificant horizontal ST-
segment depression Scint1graphy proved to be the valid 
clinical indicator. 
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Fig 1 0-Preoperative (top) and post-operative (bottom) 
thallium 20 1 MPI 1n the 45-degree left anterior oblique 
(LAO) projection in a patient who underwent coronary by-
pass surgery The preoperative rest image (top, left) is nor-
mal, but following exercise (ETT) there is an extensive de-
fect in the anteroseptal region (top right) preoperatively. 
Postoperatively both rest (bottom, left) and exercise (bot-
tom, right) are normal . The bypass graft was patent on an-
giography. 
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(Table 2). Thallium 201 is administered at the 
peak of exercise, and early images are ob-
tained. If a normal image is recorded , further 
imaging is unnecessary (Fig 2). If an abnormal-
ity is present, delayed images are recorded to 
assess the redistribution into ischemic areas 
(Fig 5). When compared with standard exercise 
electrocardiography, thallium 201 MPI is signifi-
cantly more sensitive than exercise testing in 
the detection of coronary artery disease. This 
improved sensitivity is present in patients with a 
normal resting electrocardiogram (ECG) in 
whom exercise testing is most reliable (Fig 7), 
and is found particularly in patients with an ab-
normal resting ECG, in whom ECG changes 
with exercise are often difficult to interpret or are 
uninterpretable. This is encountered in patients 
with intraventricular conduction defects, particu-
larly left bundle-branch block; left ventricular hy-
pertrophy (Fig 8); nonspecific resting ST-seg-
ment abnormalities ; and in patients tak ing 
digitalis or other medications which may alter 
the resting and exercise ECG. 
Thallium 201 also has a higher specificity 
in detection of coronary artery disease than 
standard treadmill exercise testing , as false-
positive results with thallium 201 are infrequent 
(Fig 9). 11· 19 In contrast, the incidence of false-
positive results with exercise electrocard io-
graphy may be as high as 30% in certain pa-
tient populations 21 Thallium 201 exercise imag-
ing is complementary to exercise testing , and 
diagnostic accuracy is improved when they are 
used in combination. In several series, this ac-
curacy exceeds 90% in the detection of signifi-
cant coronary artery disease. ' 7 · 19 
MPI with thallium 201 may also be of 
value in the postoperative evaluation of patients 
having coronary artery bypass graft surgery, as 
changes in regional myocardial perfusion with 
MPI have been shown to correlate well with by-
pass graft function, 22 thereby providing a non-
invasive method of determining graft patency or 
closure (Fig 1 0). 
In summary, MPI with thallium 201 is a 
new and effective noninvasive technique in the 
diagnosis of ischemic heart disease. It can re-
liably detect myocardial infarction and may be 
useful when the diagnosis of acute infarction by 
other means is uncertain. Exercise thallium 201 
imaging is the area of greatest clinical appli-
cation of MPI , resulting in improved sensitivity 
14 / COWLEY THALLIUM 201 MYOCARDIAL IMAGING 
and specificity over exercise testing alone, and 
in high diagnostic accuracy in the detection of 
coronary artery disease when used in combina-
tion with exercise electrocardiography. Thallium 
20 1 MPI is also of value in the evaluation of cor-
onary artery bypass graft function. 
Figures 1, 7, 8, and 9 are reproduced with permission 
from the American Journal of Cardiology (41 :43-51, 
1978) 
Figure 6 is reproduced by permission from the New 
England Journal of Medicine (295 1-5, 1976) 
Figure 1 0 is reproduced from Circulation (56 830-
836, 1977) by permission of the American Heart Associa-
tion, Inc. 
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Indications for Cardiac Catheterization in the 
Diagnosis and Management of Coronary 
Artery Disease 
GEORGE W VETROVEC, M.D. 
Assistant Professor of Medicine and Cardiology, and Director, Cardiac Catheterization Laboratory, 
Medical College of Virginia , Richmond, Virginia 
In 1979 coronary ang iography remains 
the standard test for diagnosing the presence 
and extent of coronary artery disease. Non-
invasive studies such as exercise test ing are 
only relative predictors of coronary anatomy. 
Therefore, to define spec ifical ly whether or not 
coronary disease ex ists in a given patient and, if 
present , to delineate its location , severity and 
the potential for bypass surgery , a coronary 
angiogram is the test to obtain . The purpose of 
this paper is to discuss indications for coronary 
angiography in the management of patients 
with established or suspected coronary disease . 
Figure 1 shows a schematic representa-
tion of the normal cardiac blood supply The left 
and right coronaries exit directly from the aorta , 
and the left main coronary divides into two ma-
jor branches, the left anterior descending and 
the circumflex vessels. It is important to note the 
extensive blood supply to the heart-mainly the 
left ventricle-through the left main coronary 
and its branches. Therefore , the left main coro-
nary is frequently considered in a special class 
when discussing coronary artery disease. Other 
important vessels include the left anterior de-
scending, the circumflex and the right coronary 
arteries . The term "single- ", " double- ," or 
''triple-vessel disease '' refers to the number of 
these three important vessels involved with sig-
nificant disease. Obstructive lesions of the coro-
Correspondence and reprint requests to Dr . George 
W Vetrovec, Box 36, Medical College of Virginia, Rich-
mond, VA 23298 . 
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naries represent the bui ld-up of atherosc lerotic 
material which decreases the vessel lumen and 
thereby decreases blood flow through the ves-
sel. During coronary ang iog raphy, rad iopaque 
dye is injected selectively into each coronary ar-
tery to allow visualizat ion of each vessel and its 
major branches. 
Figure 2 illustrates a sing le-frame cine 
from such a procedure ; the sign ificant athero-
sclerotic lesion is clearly demarcated. There-
fore , using this techn ique, the extent and loca-
tion of coronary artery lesions can be 
specifica ll y identified. 
Table 1 lists seven indications for coro-
nary ang iography. Considerable controversy 
cont inues to exist about the overall benefits of 
coronary bypass surgery and therefore it is ex-
tremely difficult to be unequivocal in li sting 
one's indications for coronary ang iography. 
However, the general gu idelines given here are 
thought to be the most reasonable , although 
clinical circumstances must be carefu ll y ana-
lyzed for each patient prior to proceeding to 
coronary angiography. 
Symptomatic Indications 
The first and probably most frequent in-
dication for coronary ang iography is failure of a 
patient to respond to reasonable medical man-
agement; the term " reasonable medical man-
agement'' is used because of the wide re-
sponse of patients to medical treatment . Some 
patients ' response is less than ideal because of 
poor drug compliance while others have intoler-
able side effects to the medications such as se-
vere protracted headaches associated with ni-
trate administration , or significant fatigue or bad 
dreams associated with propranolol. In addition, 
a prior history of asthma or congestive heart fail-
ure is a contraindication for the use of pro-
pranolol. Finally , despite adequate medical 
management, some patients remain incapaci-
tated because of their chest pain In any situa-
tion in which a patient fails to get adequate 
symptomatic benefit from medical treatment 
and/or has significant side effects associated 
with the treatment , coronary angiography 
should be considered to determine if he or she 
is a candidate for coronary bypass surgery 
Clearly 80% to 90% of patients have a signifi-
cant reduction in symptoms and medication re-
quirements following coronary bypass surgery 
and many of them remain symptom-free . 1 In a 
study of 1 00 patients randomly assigned to 
medical or surgical treatment , Mathur and 
Guinn 2 documented significantly improved 
treadmill performance for post-bypass surgery 
patients when compared with their medically 
treated counterparts. Furthermore, subsequent 
to treadmill testing , 70% of the surgical patients 
had no angina while only 20% of the medical 
Fig 1-Schematic coronary anatomy The right and left cor-
onary arteries arise from the aorta. The short main left (LC) 
artery bifurcates in to two large branches, the left anterior 
descending (LAD) artery and the circumflex (CX) artery sup-
plying most of the anterior and lateral myocardial surface. 
The right coronary (RC) artery supplies the in ferior myo-
cardium through the posterior descending (PD) artery. 
Fig 2-Left main coronary obstruct ion. The left coronary 
system seen in a lateral projection is fi lled with contrast me-
dium during a contrast injection Note critica l left main artery 
stenosis ( arrol'Yj 
group were angina-free These data emphasize 
the symptomat ic benefits of coronary bypass 
surgery 
In addi tion to symptomatic benefits of cor-
onary bypass surgery, certain subgroups of pa-
tients have improved longevity following this 
procedure . Ongoing studies will cont inue to bet-
ter delineate these subgroups, but at present 
those patients with left main coronary artery dis-
ease appear to show improved function and 
prognosis as a resu It of the bypass operation . 
This fact is well illustrated by a three-year follow-
up of the subgroup of patients with significant 
left main artery disease from the VA Coopera-
tive Study 3 In this study, 1 2 (29%) of 41 medi-
cally treated patients died in the three-year fol-
low-up compared to only 3 (7%) of 42 patients 
in the surgica lly treated group; the difference 
was significant (p ~ 0.01 ). In addition , the ben-
TABLE 
Indications for Coronary Angiography 
1. Angina inadequately responsive to reasonable medica l 
management 
2. Unstable angina 
3. Atypica l ang ina 
4 . " High-Risk" co ronary patients 
5. Undiagnosed chest pa in 
6. Heart fa ilure post-myocard ial infarct ion 
7. Recurrent ang ina post-coronary bypass surgery 
VETROVEC CARDIAC CATHETERIZATION / 1 7 
efit appeared to be greatest in those patients 
with associated right coronary disease. 
Therefore, patients who do not respond 
well to reasonable medical treatment, and who 
are surgical candidates have an excellent pros-
pect for improved functional status following by-
pass surgery. Furthermore, patients with left 
main vessel disease and perhaps yet-to-be-
proven other subgroups have improved longev-
ity following the bypass operation. 
Unstable Angina Pectoris 
A second major consideration for coro-
nary angiography is patients who have unstable 
or rapidly worsening angina pectoris; in certain 
instances, these patients may even be classified 
as having pre-infaction angina. Most cardiolo-
gists feel that such patients should be stabilized 
first, if possible, with vigorous medical treat-
ment. This philosophy is supported by studies 
suggesting that the risk of emergency coronary 
angiography and bypass surgery to patients 
with unstable angina is equal to the risk of initial 
medical management as far as morbidity and 
mortality are concerned 4 ; however, patients 
who do not respond to medical treatment are 
candidates for angiography and coronary by-
pass surgery to relieve their persistent symp-
toms. For those patients who do respond to 
medical treatment the question then arises as to 
whether they should be catheterized and, if so, 
when. Generally, it seems prudent to consider 
angiography for young, active patients with un-
stable angina even though they respond to 
medical treatment, as a review of the angiog-
raphic and historical data will show. 
Coronary angiography on large groups of 
patients who have had recent unstable angina 
have shown a 1 0% to 1 5% incidence of left 
main coronary disease. 4 5 This finding is impor-
tant because these patients have improved sur-
vival following bypass surgery. In addition, from 
5% to 20% of patients may show normal coro-
nary angiograms; variability of this number re-
lates to the criteria used in any given study for 
the diagnosis of unstable angina. When accom-
panying electrocardiographic changes are re-
quired for the diagnosis of unstable angina, the 
incidence of normal coronaries associated with 
this chest pain syndrome is reduced. However, 
identifying normal coronaries is important as 
many patients are then found to have a non-
cardiac cause for their chest pain. Rarely, indi-
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viduals may have angina with normal coro-
naries, but generally these patients do well, with 
infrequent symptoms and a much lower risk of 
myocardial infarction than those patients with 
obstructive coronary disease. Therefore, the di-
agnosis of normal coronaries allows one to be 
much more positive in reassuring the patient 
about long-term survival. In addition to these 
subgroups, a majority of the remaining patients 
with unstable angina have significant three-ves-
sel disease, a group that many feel may benefit 
from bypass surgery in terms of symptoms and 
prognosis. 
One third or more of non-surgical patients 
who have unstable angina will have a sub-
sequent unstable period within six months de-
spite medical treatment. 5 Excluding left main 
vessel disease, in randomized studies com-
paring medical versus surgical treatment for un-
stable angina, there was no significant differ-
ence in morbidity (subsequent myocardial 
infarctions) and mortality when the two groups 
were compared after four months or after 1 % 
years. 6 However, these studies emphasize the 
improved functional performance seen in those 
patients who undergo surgery. Considering the 
higher incidence of left main vessel disease, the 
moderately frequent occurrence of normal coro-
naries and the significant subsequent disability 
of medically treated patients, coronary angiog-
raphy is warranted in active individuals with un-
stable angina to better define the programs and 
appropriate treatment plan. 
Atypical Angina Pectoris 
A third consideration for coronary angiog-
raphy is in those patients who demonstrate 
atypical or Prinzmetal type angina pectoris. This 
syndrome is charactreized by chest pain at rest 
with associated significant ST-segment eleva-
tions which are transient in nature. These pa-
tients are often subject to significant rhythm dis-
turbances and/or conduction abnormalities 
with the chest pain episodes. 7 Anatomically, pa-
tients with atypical angina may have either high-
grade fixed obstructive lesions or normal coro-
naries with intermittent vessel spasm producing 
the symptoms. These patients are frequently 
difficult to manage medically, thus the dis-
tinction between significant obstructive disease 
and spasm is important from the standpoint of 
therapeutic options, as patients with significant 
obstructive disease generally benefit from by-
pass surgery whereas patients with spasm do 
not . 
High-Risk Patients 
Symptoms of angina do not correlate well 
with the extent of disease. Ideally , one would 
like to have a simple noninvasive test that would 
identify those patients who have significant left 
main vessel disease which derives so much 
prognositc benefit from bypass surgery, but no 
such test is available. However, certain exercise 
test responses are considered suggestive of se-
vere coronary artery disease which frequently 
includes left main vessel disease. Table 2 lists 
those high-risk abnormalities. Included in this 
group8 are patients who develop marked (2 mm 
or greater) ST-segment depression with exer-
cise testing , particularly at low levels of exercise 
performance. In addition , the development of 
ST-segment elevation on treadmill testing in an 
area of the electrocardiogram not showing a 
prior myocardial infarction is a significant pre-
dictor of severe proximal coronary disease if not 
of left main vessel disease. 9 Finally, patients 
who develop hypotension at nonmaximal exer-
cise performance are again likely to have signifi-
cant disease. 10 Such hypotension suggests se-
vere myocardial ischemia consistent with 
marked proximal coronary artery disease. In 
these high-risk patients coronary angiography is 
important to delineate this anatomic abnormal-
ity. 
Other high-risk patients include those who 
have a history of prior myocardial infarction and 
significant symptomatology and / or poor exer-
cise test responses , particularly if they are in the 
high-risk category listed above. Furthermore , 
subendocardial myocardial infarctions may rep-
resent another significant risk group. Fifty con-
secutive patients with a recent condition of this 
type at the Mayo Clinic 1 1 showed a high fre-
quency of symptomatic disability in a short-term 
ten-month follow-up. Fifteen patients (30%) had 
significant stable angina pectoris and nearly 
half , 23 (46%) of 50 , developed unstable angina 
over the short time of the study; only 1 2 (24%) 
of the 50 remained angina-free. Considering 
the frequency of significantly limiting symptom-
atology in this study, early angiography in pa-
tients with a recent subendocardial myocardial 
infarction seems warranted to identify those pa-
tients who are candidates for bypass surgery, 
particularly in physically active individuals. 
TABLE 2 
Exercise Test Predictors of Potentially Severe 
Coronary Disease 
1 . Marked ST-segment depression 
2. ST-segment elevation in an area of noninfarction of 
the ECG 
3. Hypotension at nonmax imal performa nce 
Chest Pain Diagnosis 
To this point , the discussion has centered 
on the diagnosis of the extent of coronary dis-
ease. Another consideration for coronary angi-
ography is specifically to exclude the existence 
of coronary disease. Not every patient with 
vague, intermittent or poorly defined chest dis-
comfort is a candidate for a coronary angio-
gram ; however, there are those in whom non-
invasive studies, including exercise testing and 
perhaps thallium imaging , fail to demonstrate 
clearly whether or not coronary artery disease 
exists. Most of these patients have symptom 
complexes with components that are both typi-
cal and atypical of angina . In addition , the con-
cern about the possibility of coronary disease 
may be limiting these patients ' lifestyles . In such 
instances, coronary angiography is warranted 
to provide a definitive diagnosis. 
Congestive Heart Failure 
Congestive heart failure after a myocardial 
infarction can be a difficult management prob~ 
lem , particularly if it does not respond to routine 
medical treatment for heart failure. Left heart 
failure may be manifested either as a congested 
state with recurrent pulmonary edema and 
shortness of breath or as a low-output state in 
which the patient's major complaints relate to 
low forward cardiac output, that is, fatigue, 
weakness and exercise intolerance without 
chest pain. Clinical findings frequently include 
either a mitral regurgitation murmur, ventricular 
gallop rhythms and / or a contour on apex pal-
pation , suggesting a left ventricular aneurysm . 
Anatomically , one wishes to know whether or 
not there is a localized aneurysm or significant 
mitral regurgitation . Cardiac catheterization of 
patients who fail to respond to routine treatment 
will delineate the severity and location of left 
ventricular wall motion abnormalities as well as 
whether or not there is significant valvular in-
sufficiency. In addition , coronary angiograms 
identify obstructive vessels which may exist in 
the areas of remaining functional myocardium. 
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Patients with severe diffuse non-localized left 
ventricular dysfunction are generally not can-
didates for bypass surgery, because in such in-
stances the operative risk is increased and 
there is no benefit in terms of reducing heart 
failure. However, if a localized , correctable me-
chanical problem exists such as a left ventricu-
lar aneurysm or significant mitral regurgitation, 
the condition of these patients may be signifi-
cantly improved by surgical correction of the 
appropriate defect with or without additional by-
pass surgery as dictated by the coronary anat-
omy. 
Recurrent Angina Pectoris Post-Bypass 
Surgery 
Finally , those patients who have pre-
viously undergone bypass surgery and who de-
veloped recurrent angina pectoris may need an-
giography; as the frequency of bypass surgery 
increases, so will the numbers of such patients. 
Two factors determine the need for repeat coro-
nary post-bypass angiography. First, if the re-
current angina occurs within one to two months 
following bypass surgery, it is likely that one or 
more vein bypass grafts have occluded. 12 In this 
event the preoperative angiograms should be 
reviewed and the anatomy discussed with the 
surgeon. If the distal vessels suggest poor distal 
runoff either angiographically and / or at the time 
of surgery and the post-bypass flows were poor,· 
it is unlikely that reoperation will carry any better 
chance of maintaining a patent graft, and con-
sideration of repeat catheterization should be 
postponed unless medical treatment fails to be 
effective. Conversely, if flows were good at the 
time of surgery and the distal runoff appeared 
adequate, graft failure might be caused by a 
technical problem resulting from surgery Reo-
peration could conceivably benefit such a pa-
tient, thus a repeat angiogram is warranted ; 
however, early recurrent angina is most often 
seen in patients with severe distal disease. 
A further consideration for angiography is 
the patient who has experienced marked symp-
tomatic improvement for a long time following 
the bypass operation. When recurrent angina 
occurs in such a patient , the anatomic problem 
is generally not in the graft but represents pro-
gression of the disease in the native circulation, 
either distal to the graft insertion or in other non-
graftable vessels . Depending on the symptom-
atology and the state of the other vessels at the 
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time of surgery, it is reasonable to consider a re-
peat study in these patients, looking for other 
potentially graftable vessels. 
The foregoing discussion should provide a 
reasonable approach to the utilization of cardiac 
catheterization and coronary angiographic tech-
niques in the diagnosis and management of pa-
tients with coronary artery disease. Combining 
the functional performance information derived 
from noninvasive tests with the anatomic abnor-
malities demonstrated with coronary angiogra-
phy provides the most thorough evaluation of 
patients with coronary disease. The information 
derived from coronary angiography is frequently 
important in the prognostic and therapeutic de-
cisions regarding patients with coronary dis-
ease. 
Figures 1 and 2 are reproduced with permission from 
B Soto, RO Russell , RE Morask1 Radiographic Anatomy of 
the Coronary Arteries: An Atlas. Mount Kisco (New York), 
Futura Publishing Company, Inc , 1976. 
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Afterload Reduction Therapy for Congestive 
Heart Failure 
DEAN T. MASON , M.D . 
From the Section of Cardiovascular Medicine, Departments of Medic ine and Physiology, University of 
California , School of Medicine , Davis , Ca li forn ia, and Sacramento Medical Center, 
Sacramento, Ca lifornia 
The most important recent advance in the 
medical management of patients with acute and 
chronic congest ive heart failure has been the 
applicat ion of system ic vasodi lator drugs to re-
duce ventricu lar afterload, thereby improving 
low cardiac output and decreasing increased 
venous pressure. Although such drugs have 
been employed for several years to treat essen-
ti al hypertension, hypertensive heart failure , 
acute hypertensive crises , and angina pectoris , 
only in the past five years has their use become 
widely popular in the therapy of normotensive 
heart failure. 1 While it can be reasoned that the 
vasodilator approach is a log ical therapeutic ex-
tension of fundamenta l determinants regulating 
cardiac funct ion known for many years, it is 
nevertheless intriguing that consideration has 
been delayed until the present time of such a 
useful concept as afterl oad reduction therapy in 
heart failure. 
Regulation of Cardiac Function 
The intact heart is normally governed by the 
intimate integration of four principal determi-
nants regulating stroke volume and cardiac out-
put (Fig 1 ): 1) preload (ventricular end-d iastolic 
volume} , 2) contractility (variable force of ven-
tricular contraction independent of load ing}, 3) 
Supported in part by Research Program Project Grant 
HL-14 780 from the National Heart , Lung and Blood Insti-
tute, National Institutes of Health , Bethesda, MD. 
Correspondence and reprint requests to Dr. Dean T. 
Mason, Professor and Chairman , Cardiovascular Medicine, 
University of California, School of Medicine , Davis, CA 
95616 
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afterload (ventricular systo li c tension during 
ejection} , and 4) heart rate. 2 The terms " cardiac 
function " and " ventricular performance " are 
used in the general sense to refer to the com-
bined action of these four determinants of car-
diac output, and not necessarily to the single 
determinant of cont ract ilit y. The disturbed 
mechan isms operative in all types of c linical 
heart disease can be eva luated and accu rately 
measured within the framework of isolated or 
composite disorders of these fou r maior de-
terminants of cardiac performance 3 Besides af-
fording a better understanding of the manner in 
which various types of heart disease lead to dis-
turbed pump performance , appreciation of the 
determinants of cardiac function (Fig 1) pro-
vides the rationale for an org anized approach to 
the integration of therapy in the management of 
congestive heart failure. 4 
Rationale of Afterload Reduction Therapy 
Facilitation of ventricular emptying lead ing to 
increasing lowered stroke volume is the funda-
mental objective of therapy for heart failure . 
Conventional treatment of congest ive heart fail -
ure has focused primarily on increasing ven-
tri c ul ar stroke vo lume and cardi ac output 
through the use of direct pos itive inotrop ic 
agents and concomitant diuretic therapy. In the 
case of patients with coronary heart disease in 
whom acute and chronic pump failure results 
principally from the impairment and loss of myo-
cardial contractile units, an increase in the in-
otropic state of the remaining functioning heart 
musc le may insuff icient ly augment cardiac per-
formance. The powerful inotropic st imulus of 
card iotonic agents may also increase overall 
myocardial oxygen demand (MV02), which is 
potentially detrimental in acute ischemic heart 
disease. In contrast to elevating low stroke out-
put by direct inotropic stimulation in heart fail-
ure, reducing impedance to left ventricular ejec-
tion by administrati on of systemic arteriolar 
dilator drugs provides a unique therapeutic 
mechanism for the augmentation of pump per-
formance by increasing ventricular emptying , 
while also diminishing MV0 2 . 5 
Determinants of Ventricular Afterload 
As with ventricular filling (preload) , several 
factors influence afterload and impedance to 
left ventricular outflow. The load or tension that 
the left ventricle must develop to e1ect stroke 
volume constitutes ventricular afterload. After-
load is defined as the wall tension during left 
ventricular ejection 5 The two principal determi-
nants of afterload are systolic pressure and 
rad ius of the ventricle , according to the Laplace 
formula. In turn , systolic pressure is related to 
impedance to blood flow in the aorta, and the 
radius of the ventricu lar chamber is related to 
left ventricular volume (preload). 
Determinants of Aortic Impedance 
Impedance to left ventricular ejection is the 
instantaneous relation between the rate of 
change in aortic pressure and aortic flow. 5 Left 
ventricular outflow impedance is governed pri-
marily by two factors 1 ) the compliance (rela-
tion of pressure to flow) in the large arteries; and 
2) the total peripheral vascular resistance (the 
rate of runoff from the systemic arterial tree) 
which is determined principally by the radius or 
cross-sectional area of the systemic arteriolar 
beds. Of these factors regulat ing impedance, 
systemic arteriolar resistance is the most impor-
tant and the variable most subject to modifica-
tion by pharmacologic vasodilation 
Determinants of Left Ventricular Energetics 
In the setting of impai red ventricular perform-
ance, elevation of outflow impedance results in 
declines of the extent and rate of fiber shorten-
ing and reduction in the ejection fraction with 
the consequent elevation of left ventricular filling 
pressure (preload) Thus stroke volume must be 
maintained at increased energy costs related to 
the increase in intramyocardial wall tension (af-
CONTRACT I LITY 
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Fig 1-Representation of the four principal determinants of 
cardiac output 
terload) (Fig 2). ~ In severe pump failure, eleva-
tions of impedance and preload (afterload prod-
uct), which are inherent consequences of the 
heart fai lure state , result in the rise of MV02 . 
This ri se in MV02 leads to potenti al myocardial 
ischemia and continued impairment of pump 
function , causing greater sympathetic-induced 
rise of peripheral vascu lar resistance with result-
ant increases in ventricu lar afterload and pre-
load. Thus a progressively deleterious cycle ad-
versely affect ing MV02 and pump performance 
is set in motion by th e operat ion of co m-
pensatory mechanisms attempting to maintain 
cardioc ircu latory integrity. Systemic vasod ilator 
therapy, which produces reductions in both im-
pedance and preload , interrupts this harmful 
chain of events wh ile augmenting cardiac out-
put , diminishing pulmonary congest ion and im-
proving myocardial energetics . 5 
Clinical Use of Systemic Vasodilators 
While it has been two decades since 
Bu rch produced gangl ion ic blockade with the 
intravenous vasod ilator, hexamethonium , in the 
relief of intractable pulmonary congestion due 
to left heart failure6 and Johnson diminished 
acute pulmonary edema by sublingual nitro-
glycerin in left ventricular dysfunction , 1 the ex-
pressed purpose of those two isolated reports 
was clearly the reduction of increased left ven-
tricular preload and elevated systemic venous 
tone in the amelioration of backward failure (pul-
monary congest ion) via peripheral venod ilation 
That vasodilators might be useful in decreasing 
raised peripheral arteri al resistance to diminish 
WALL TENSION--IMV?2I-- HEART RATE 
CONTRACTILITY 
FIG 2-Representation of the three major determinants of 
myocardial oxygen consumption (MV02) lntramyocardial 
systolic wa ll tension is left ventricular afterload which is a 
product of preload (left ven tr icular volume) and impedance 
(systolic blood pressure) 
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f lG 3-Ventricular fu nc tion curves relating ventricular per-
formance (cardiac output) to ventricular preload (ventricular 
end-diastolic pressure). Curve 1 represents increased car-
diac contractility , while curves 0 1 and 0 2 indicate progres-
sively severe reduct ions in contractili ty. 
pump outf low impedance with improvement in 
forward fai lure (low cardiac output) was not ap-
preciated at that time . 
The pharmacolog ic approach of vasod ila-
tor therapy for impedance reduction was first 
employed c lin ica ll y in norm otens ive severe 
heart failure by Majid and assoc iates in 19 71 . 8 
Thus, infusion of the alpha-adrenergic block ing 
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FIG 4- Ventricular funct ion curves relatin g ventricular per-
formance (cardiac output) to the aortic impedance com-
ponent (total systemic vascular resistance) of ventricular af-
terl oad Th is relati onship becomes inc reas ingly steep 
(greater depression of cardiac output) as vent ricular function 
declines from the normal curve to the curves 0 1 , 0 2 and 0 3 
indicating progressively grea ter depression of ca rdiac con-
tractility . As card iac dysfunct ion worsens, the point of ven-
tricular function (closed circles) of the progressively failing 
ventricle on the spectrum of curves shifts to a higher imped-
ance component of alterload. 
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agent , phentolamine, in acute myocardial in-
farct ion was observed to result in the decline of 
elevated systemic vascular resistance , accom-
panied by the ri se of low cardiac output and the 
fall of elevated pulmonary artery pressure, with-
out substantial alterations in systemic arterial 
pressure and heart rate . The modern era of af-
terload reduct ion gained momentum following 
reports of similar hemodynamic benefits 
achieved by intravenous nitroprusside in acute 
myocardial infarction patients 9 - 11 The vasodila-
tor concept spread rapidly and has now been 
extended to the management of severe chronic 
cardiac dysfunction of various types 5 12 - 18 
As to why the idea of afterload reducti on 
therapy of heart fa ilure was not recog ni zed 
sooner, it seems to me that this delay has been 
largely the result of a lack of understanding , un-
til recently , of the criti cal relationships between 
periph eral c irculatory dynamics and cardi ac 
performance 19 Furthermore , the relation of car-
diac output to peripheral vascu lar activity is de-
pendent upon left ventricular contractility When 
the heart is normal, cardiac output is principally 
governed by systemic venous tone with the left 
ventricle operating on the steep ascending limb 
of its Frank-Starling curve (outflow-preload rela-
tion) (Fig 3 ); aorti c impedance reduction is of 
little importance . In contrast , in the presence of 
left ventricular dys function, arteri al resistance is 
elevated and cardiac output becomes strongly 
dependent on outflow resistance (Fig 4) Thus, 
the interpl ay between impedance (arterial resis-
tance bed) and preload (venous capac itance 
bed) reduct ions is that preload is more impor-
tant than impedance in the normal heart (car-
diac output declines) (Fig 3) , while in the failing 
heart , impedance reduction predominates over 
preload dec line (cardiac output ri ses) (Fig 4) 
While profound periph eral arteri al and 
venous constricti on accompanies chronic heart 
failure,2 only recently has it become appreci-
ated that the heightened adrenergic activity in 
response to lowered ca rdi ac output , while 
seemingly useful in maintaining blood pressure, 
may result in a greater level of increased sys-
temic vascular resistance than is required to 
sustain arterial pressure, and thus thi s refl ex 
adaptive mechanism may actually further de-
crease card iac output (Fig 4) 1 A harmful cyc le 
is thereby provoked in which the heart failure 
patient reaches a greater depression of hemo-
dynamics than is really optimal , systemic vascu-
lar resistance being higher and cardiac output 
lower than are salutary . In addition , systemic 
venoconstriction may also become excessive in 
chron ic heart failure. Consequently, there oc-
curs greater elevation of left ventricular end-
diastolic pressure than is required relative to the 
lowered card iac output on the depressed and 
flattened ventricular function curve character-
istic of impaired contractility. Importantly, vaso-
dilator therapy possesses the ability to interrupt 
this deleterious sequence of events by partially 
counteracting the compensatory sympathetic 
reflex mechanism. ' 
Spectrum of Systemic Vasodilator Drugs 
A variety of intravenous, oral , sublingual 
and cutaneous agents are now readily available 
which provide a spectrum of actions which re-
sult in the elevation of lowered cardiac output 
by reducing peripheral vascu lar resistance and / 
or decline of increased ventricular end-diastolic 
volume (ventricular preload) by lowering venous 
tone. These drugs produce disparate modifica-
tions of cardiac function by their differing altera-
tions of preload versus impedance, which are 
dependent upon their relative effects on sys-
temic arteriolar resistance and venous capaci~ 
tance vessels characteristic of each agent (Fig 
5) 2 0 In addition, these drugs cause concomitant 
reduction in MV02 which is of special impor-
tance in ischemic heart disease. 
Therefore, modulation of cardiac function 
by the vasod ilators is determined by their rela-
tive preload and impedance effects (Fig 6). 
Thus, the nitrates 15 principally cause venod ila-
tion (decrease elevated left ventricular end-dias-
tol ic pressure); nitroprusside, 2 ' phentolam ine, 2 0 
and prazosin2 1 produce balanced arterial and 
venous dilation (decrease elevated left ventricu-
lar end-diastolic pressure and increase lowered 
cardiac output) provided left ventricular filling 
pressure is maintained at the upper limit of nor-
mal '?; while hydralazine '3 predominantly effects 
arteriolar dilation (increases lowered cardiac 
output). With depressed cardiac output plus 
highly elevated left ventricular end-d iastolic 
pressure and elevated peripheral vascular resis-
tance, nitrates 'b also achieve some increase of 
lowered card iac output by markedly reducing 
increased peripheral vascular resistance. Com-
bined nitroprusside and dopamine22 or dobuta-
mine synergistically increase low cardiac output 
and decrease raised left ventricular end-dias-
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FIG 5-Diagram of the spectrum of actions of systemic 
vasodilators on the peripheral arterial tree and systemic 
venous bed. CO = cardiac output ; EDP = left ventricular 
end-diastolic pr~ssure ; LVEDV = left ventricular end-dias-
tolic volume; MV0 2 = myocardial oxygen consumption; IV 
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CONGESTION 
LVEDP(mm Hg) 
FIG 6-Relationship between cardiac output (CO) and left 
ventricular end-diastolic pressure (LVEDP) in a normal sub-
ject (left curve) and a patient with congestive heart fa ilure 
(CHF) (right curve) Point A indicates the point of operation 
of the dysfunctioning left ventricle in CHF. The intermediate 
curve ( 1) is the improved relation between CO and L VEDP 
after the administration of digitalis (Point E), nitroprusside 
(NP) to above LVEDP of 12 mm Hg (Point B), and NP to be-
low LVEDP of 12 mm Hg (Point C) with the addition of dex-
tran (Point B). Prazosin and combined hydralazine-nitrate 
therapy are the same as NP from Point A to Point B. The en-
hanced CO and reduced L VEDP following the administra-
tion of phentolamine (PT) are shown by Point F. Hydralazine 
therapy can be represented from Point A to Point E. It is in-
structive that the improvements from Point A on the lowest 
ventricular function curve to Point B on the intermediate 
function curve (1) after NP administration and to Point F af-
ter PT was given are not the result of increased contractility; 
rather, they are due to the enhanced relation between CO 
and L VEDP that the reduction of impedance to left ventricu-
lar ejection NP and PT allow. Point D on the CHF curve is 
the LVEDP after diuretic or nitrate therapy. The intermediate 
curve (2) demonstrates the improvement in CO and de-
crease of L VEDP achieved with combined NP and dopa-
mine therapy (Point G) The horizontal broken line indicates 
the lower limit of normal for CO and the vertical broken line 
indicates the upper limit of normal of LVEDP. Congestion = 
pulmonary congestion. 
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tolic pressure Mechanical counterpu lsation 
aid s nitroprusside in acute myocardial in-
farction. The 30-minute venodilator action of 
sublingual nitroglycerin?3 ? 4 is extended by 4 to 
6 hours by cutaneous nitroglycerin ointment, 20 
oral isosorbide dinitrate, 10 oral pentaerythritol 
tetranitrate, ?6 and by sustained-release nitro-
glycerin capsu les. ?1 Ambu latory oral vasodilator 
therapy is provided by long-acting nitrates' 0 (re-
lieve pulmonary congest ion) ; hydralazine ' 3 (im-
proves fatigue) ; and prazosin alone, ' 5 ·?8 com-
bined nitrate-hydralazine, ?9 and comb ined 
prazosin-hydralazine" (improve both dyspnea 
and fatigue). 
Conclusions and Future Directions 
Since activi ty of the renin-angiotensin sys-
tem is increased in cardi ac dysfunction , 2 ang io-
tension II contributes in part to the increase of 
total peripheral vascular resistance character-
istic of the heart fa ilure state. Furthermore , this 
renin mechanism is st imul ated in most in-
stances of chron ic systemic vasod ilator therapy 
which attenuates systemic arteri olod ilation pro-
duced by such treatment. Because recent evi-
dence has been provided that admin istration of 
angiotensin-converting enzyme inhibitor in pa-
tients with heart fa ilure resu lts in dilation of the 
peripheral arteri al bed with an increase in car-
diac output and decrease in left ventri cu lar fill-
ing pressure , considerable attent ion is now 
being focused on the eff icacy of oral and intra-
venous converting enzyme inhibitors alone and 
in combination with convent ional system ic vaso-
dilators in c li nical heart failure. 30 In add ition , the 
vasodilator properties of the prostaglandins are 
also under evaluation in heart failure therapy . 
The initial administration of the vasodila-
tors to congest ive heart failure patients is usu-
ally accompanied by a favorable diuresis. How-
ever , with prolonged use of the agents, body 
fluid accumulation often takes place, requi ring 
greater dosage of concomitant diuretics. While 
oral furosemide is generally useful in this re-
spect , the administration of spironolactone has 
been particularly benefic ial in effecting diure-
sis, 3 ' probably caused by vasod ilator-st imula-
tion of the renin axis , resulting in increased al-
dosterone secretion. 
With the prolonged use of each of the oral 
vasodilators in the ambulatory treatment of se-
vere congestive heart failure , tolerance to the 
agents may develop in some individuals after 
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several months. In the case of prazosin, toler-
ance can occur in approximately one third of 
patients after six months of effective therapy 32 
This tolerance is surmountable with a return of 
prazosin effi cacy by increasing the dose of the 
drug, or by the brief discontinuation of the agent 
for a few weeks , or by switching for a short pe-
ri od to another vasodilator regimen such as 
trimazosin 33 or comb ined nitrate-hydralazine 
Not a single instance of tachyphylaxis with re-
peated prazosin administration has been ob-
served in over 1 50 heart failure patients to 
whom the agent has been given for either inves-
tigational or therapeutic purposes at our inst itu-
tion . The few reports of apparent prazosin 
tachyphylaxsis can each be readily attributed to 
faulty study design and/or incorrect inter-
pretation such as those by Chatterjee , 34 Packer 
et al, 34 and Elkayam et al. 36 In contrast , the 
chron ic use of hydralazine in heart fa ilure, be-
sides possible tolerance and the occasional 
side effects of the lupus erythematosus syn-
drome and peripheral neuropathy, may cause 
hydralaz in e- induced tachycardia , a frequent 
and serious complication , 31 lead ing to poten-
tially lethal dysrhythmias , angina pectoris, and 
left ventricular pump deterioration. 
The most important question as yet unan-
swered is the effectiveness of vasodilator ther-
apy in acute and chron ic refractory heart failure 
and in reducing complicat ions and mortality. Al-
though some preliminary stud ies have been en-
couraging , the definitive answers have not yet 
been established If myocardial ischemia plays 
an important role in essential hypertension, car-
diomyopathies and chron ic coronary heart dis-
ease, then the increased ventricular filling pres-
sures in these cond itions probably contribute to 
sustained subendocard ial ischemia with resu lt-
ant progression of cardiac dysfunction ' Pro-
vided this mechanism is operative , then reduc-
tion of increased filling pressure by vasodi lators 
should improve subendocardial perfusion and 
thereby diminish morbidity and extend longev-
ity 
It is remark ab le how quickly system ic 
vasodilator therapy has become established as 
an important new medical treatment for both 
acute and chron ic heart failure. ' 9 Perhaps no 
other recent therapeutic concept in cardiovas-
cular medicine has been so rapidly translated 
into practical clinical management as that of re-
ducing left ventricular afterload by means of 
vasodilator drugs. In our thinking about the 
management of congestive heart failure, it is ap-
parent that a change of focus has occurred 
from emphasis on contractility prevalent in the 
past decade to innovative considerations of car-
diac unloading by agents that primarily relax 
vascular smooth muscle without direct actions 
on the heart. ' In consort, reexamination of the 
proper role of the digitalis glycosides is taking 
place. 
Some clinicians maintain that the vasodila-
tors are important as adjuncts in severe heart 
failure for use when traditional means are in-
adequate , to be added only in combination with 
digitalis and diuretics; others already view the 
vasodilators as equal or even better alternatives 
than the conventional agents. In the difficult cir-
cumstance of refractory acute or chronic heart 
failure , the combination 'of vasodilators and 
powerful cardiotonics such as dopamine (Fig 6) 
or dobutamine in hospital situations, ~ 2 and digi-
talis38 or promising new oral positive inotropics 
on the horizon in outpatient settings,' provide 
the most potent pharmacologic augmentation of 
pump function possible. It is probable in the fu-
ture that as more experience is gained with the 
vasodilators and as newer agents become avail-
able , the systemic vasodilators will be utilized as 
frequently as digitalis in the standard treatment 
of congestive heart failure . 
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Medical Management of Angina 
ANDREA HASTILLO, M.D. 
Assistant Professor of Medicine, Division of Cardiology, and Director, Coronary Intensive Care Unit, 
Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, 
Richmond, Virginia 
Evaluation of medical therapy of angina 
pectoris can be approached in many ways, but 
the objectives remain the same: (1) to relieve 
the acute attack of angina pectoris, (2) to pre-
vent its recurrence, (3) to allow the patient to 
lead a normal lifestyle or, at least, one that is 
acceptable to him or her, and (4) to prevent 
myocardial infarction. 
Major problems are incurred when one at-
tempts to evaluate the natural history of angina 
pectoris with the effects of various treatments. 
Angina pectoris is a subjective complaint and 
therefore the response to therapy is also sub-
jective. As angina frequently waxes and wanes, 
improvement of the patient 's condition does not 
necessarily indicate a direct correlation with 
treatment , nor does the fact that a patient has 
angiographically proven coronary artery disease 
and chest pain mean that the coronary lesion is 
causing the patient's complaint Furthermore, 
many patients treated for angina pectoris who 
were later catheterized demonstrated that, de-
spite the fact that they had c lassical angina, up-
wards of 1 0% to 20% of them had insignificant 
coronary artery disease. 1 
Thus there are problems in defining the 
criteria by which to judge the patient's response 
to medical therapy Electrocardiograms as well 
as exerc ise stress testing may show false-posi-
tive as well as false-negative patterns. Despite 
the fact that not all ang iographically demon-
strated lesions cause symptoms, coronary angi-
ography remains the best method by which to 
judge the etiology of the patient 's complaint. In 
serving as the standard by which to define the 
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presence of coronary artery disease it also pro-
vides a basis for the determination of the effec-
tiveness of both medical and surg ical inter-
ventions. 
When correlating the natural history of 
ang ina pectoris and its treatment to this stan-
dard , one should remember that there are dif-
ferent types of angina Basically , patients dem-
onstrate either simple stable angina or unstable 
angina-the latter often being termed ''pre-
infarction angina" or intermediate syndrome. 
After reviewing a number of c linical studies, it 
becomes apparent that different investigators 
have different definitions of the forms of the 
ang ina they describe and hence these studies 
are not always comparable . The prognosis of 
angina varies with the form of angina being con-
sidered. In addition , when the true natural his-
tory of angina pectoris cou ld have been stud-
ied-that is , befo re medica l or su rgi cal 
intervention was possible-arteriography was 
not available. Al l of these factors have pre-
c luded the exact determination of the effective-
ness of medical therapy based on the true natu-
ral history of angina pectoris. At the present 
time , there is no means by which such a study 
could be done. Despite all the problems and 
lack of exactitude, one can evaluate, to some 
extent, how modern medical therapy may or 
may not help the patient reach the therapeutic 
goals outlined above. 
In approaching the medical management 
of angina, one must be aware that not all angina 
is the result primarily of coronary artery disease. 
As mentioned earlier, there are other causes of 
angina such as arrhythmias, severe anemias, 
aortic valve disease, hypertensive cardiovascu-
lar disease, and idiopathic hypertrophic sub-
valvular aortic stenosis which need to be ex-
MCV OUARTERL Y 1 5(1) 29-33, 1 979 / 29 
eluded or , if included, to be treated. In many 
instances therapy (which may include surgery) 
aimed at these particular abnormalities may al-
leviate the patient's angina and make the use of 
specific antianginal drugs unnecessary. 
The physician should first try to remove 
any recognized cause of the angina. The next 
step should be an attempt to change the pa-
tient 's lifestyle without turning the individual into 
a cardiac cripple. The physician should advise 
the patient to stop smoking , avoid situations 
which might precipitate angina, avoid extreme 
environmental hazards , lose weight if neces-
sary, and switch to an appropriate diet to de-
crease, or possibly reverse the progression of 
the atherosclerotic process. Participation in 
physician-approved exercise programs may al-
low the patient to maintain an acceptable life-
style with a minimum of pain. If the patient is un-
happy with the changes in lifestyle or if the 
angina persists , the physician must employ ad-
ditional medical (nitroglycerin may have already 
been prescribed) or surgical therapy . 
To understand why certain drugs are used 
for the relief of angina, one needs to understand 
the pathophysiology of ischemia (Fig 1 ). An indi-
vidual develops angina or ischemic pain (which 
may be manifested by sudden death, angina 
pectoris , myocardial infarction , or the inter-
mediate syndrome) when the myocardial oxy-
gen demand exceeds the myocardial oxygen 
supply. Basically , medical therapy attempts to 
decrease oxygen demand whereas surgical 
therapy attempts to improve oxygen supply. 
Medical therapy for noncoronary-artery-
disease-i nd uced angina pectoris may also 
involve changes in the myocardial oxygen-
demand. For instance, treatment of hyper-
tension reduces intramyocardial tension and 
thus decreases oxygen demand. Treatment 
with digitalis of heart failure associated with 
angina may decrease angina by lowering both 
the ventricular volume and the heart rate, and 
this , too, reduces oxygen demand; also, by 
lowering the left ventricular end-diastolic pres-
sure, coronary vascular resistance is theoreti-
cally decreased and the subendocardial oxygen 
supply improved. Although digitalis increases 
the contractile state, thus increasing oxygen de-
mand , it is hoped that the abatement in heart 
rate and ventricular volume will produce a 
greater decrease in oxygen demand, thereby 
relieving the angina. 
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Cigarette smoking causes undesirable ef-
fects on both oxygen supply and oxygen de-
mand; it increases the heart rate and causes 
vasoconstriction , both of which increase oxy-
gen demand , and it also decreases the oxygen 
supply by shifting the oxygen hemoglobin dis-
sociation curve so that hemoglobin releases ox-
ygen less readily to the tissues. In addition, 
smoking increases the carbon monoxide con-
tent of the blood , which is bound by hemoglobin 
in preference to oxygen ; this, too, decreases 
the oxygen supply. 
Treatment with certain drugs which can 
reduce or alleviate the angina may be indicated. 
Specific antianginal drugs include nitroglycerin , 
isosorbide dinitrate , topical nitroglycerin , pro-
pranolol and metoprolol . 
The various nitrates decrease angina by 
causing peripheral venous pooling, thus lower-
ing the intraventricular volume which lessens 
oxygen requirements. lntraventricular pressure 
may also abate , thereby decreasing coronary 
vascular resistance and theoretically improving 
subendocardial blood flow. Nitrates may also 
lower arterial blood pressure and , as a result, 
effect a decrease in impedance to blood flow; 
hence, less intraventricular tension will be nec-
essary for blood to be ejected. Problems occa-
sionally arise if a decrease in blood pressure 
caused by nitrates produces reflex tachycardia 
which in turn causes an increase in the con-
tractile state of the myocardium. Both the in-
creased heart rate and the increased con-
tractility will increase oxygen demand and may 
cause angina Furthermore, marked hypoten-
sion may develop with the administration of sub-
lingual nitroglycerin which may decrease oxy-
gen supply. However , these problems are 
infrequent. 
The broad beta-blocker, propranolol , and 
the more specific beta-one-blocker, metoprolol, 
both decrease oxygen demand2 by decreasing 
the heart rate, the force of myocardial con-
tractility, and the systolic blood pressure . The 
theoretical problems of beta-blockers causing 
increased ventricular volume which in turn in-
creases oxygen demand and left ventricular 
end-diastolic pressure , thus producing increas-
ing coronary resistance and decreasing oxygen 
supply, is usually not of clinical significance. 
Contraindications for the use of these drugs, 
however, are very important. If the patient's 
heart rate prior to institution of therapy is 45 or 
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Fig 1-Schematic representation of determinants of myocardial oxygen demand and myocardial oxygen supply. When the de-
mand is greater than the supply, angina may develop 
50, beta-blockers should not be used or else 
used with extreme caution. Insulin-dependent 
diabetics who are poorly controlled or who are 
unreliable, in general, are not candidates for 
beta-blocking drugs. Propranolol should not be 
used on patients with severe bronchospastic 
disease. Metoprolol, being a more specific 
beta-one-blocker, theoretically should not cause 
as many problems as propranolol, especially 
with brochospastic disease; however, it may be 
desirable to have these patients on a beta-one 
agonist prior to the institution of metoprolol. 
Though the dose of these various anti-
anginal drugs will vary from individual to individ-
ual, a few broad guidelines can be set (Fig 2) 
Nitroglycerin is usually the first anti-anginal drug 
utilized. Sublingual nitroglycerin should be be-
gun in the lowest dose possible and the first 
dose should be given in the physician's office 
while the patient is seated to observe any unto-
ward reactions. Some patients complain of se-
vere headaches and a few may be intolerant of 
the drug for this reason. The dose of nitro-
glycerin should be increased as necessary to 
achieve control of the patient's angina Sub-
lingual nitroglycerin is not solely used for acute 
anginal attacks but may also be given prophy-
lactically to patients who routinely develop an-
gina with certain situations such as climbing or 
engaging in anxiety-producing confrontations. 
If angina is frequent, if the patient cannot 
tolerate the nitroglycerin or if it is advisable to 
avoid using prophylactic nitroglycerin, then ei-
ther the long-acting nitrates or propranolol 
should be used . Neither the long-acting nitrates 
nor propranolol are effective in terminating the 
acute anginal attack; lsordil®'s effect lasts 
longer than the 1 5-minute changes induced by 
nitroglycerin and is often better tolerated by the 
patient. However, the duration of lsordil®'s ac-
tion is variable, and is partially determined by 
the route of administration. Sublingual lsordil® 
has a shorter onset of action than the oral form , 
but its effect lasts only 3 to 4 hours whereas 
oral lsordil® may be given at 4- to 6-hour inter-
vals. Topical nitroglycerin action lasts for from 4 
to 6 hours. 
The dose of sublingual lsordi l® may vary · 
from 2. 5 mg up to 20 mg every 3 to 4 hours, 
depending on the patient 's response. If one 
uses oral lsordi l®, it is important to realize that 
higher dosages must be used compared to sub-
lingual lsordil® to produce the same hemo-
dynamic effects; however, the use of oral lsor-
di l® may be preferred, as it is often better 
tolerated by the patient. Though one often starts 
with at least 1 0 mg of oral lsordil® every 6 
hours, usually at least 20 mg every 6 hours is 
necessary to achieve improvement. The dosage 
of topical nitrog lycerin, like lsordil®, must be tit-
rated by the patient's response. Its advantage is 
that a single evening application may prevent 
nocturnal angina and permit the patient to sleep 
through the night ; a major disadvantage is that , 
as a paste, it may be aesthetically unpleasing . 
Topical nitroglycerin is usually applied in terms 
of inches or fractions of an inch and its efficacy 
is partially dependent upon the site of appli-
cation- better absorption obtained when it is 
applied above the waist-and the area over 
wh ich the paste is applied- the greater the 
area, the better the absorption 
All nitrates have the potential problem of 
decreasing blood pressure and causing reflex 
tachycardia. Patients can usually tolerate head-
ache, although aspirin or acetominophen may 
have to be added to the regimen. 
Propranolol is an effective drug for treat-
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Block Hypoglycemic Symptoms 
Fig 2--Commonly used anti-anginal drugs. 
ing angina and the best results appear to occur 
in patients who have either an elevated blood 
pressure or an increased heart rate prior to insti-
tution of the drug. In treating angina, one usu-
ally prescribes propranolol every 6 hours and 
the total daily dose is at least 1 60 mg. The drug 
is begun at a lower dose of 1 0 to 20 mg every 6 
hours and increased every 2 to 3 days, depend-
ing on the patient 's response in terms of blood 
pressure, heart rate and symptoms. One should 
carefully evaluate the patient for the appear-
ance of peripheral edema, rales, weight gain or 
other evidence of heart failure . The end point 
for increasing the propranolol varies: precipi-
tation of congestive heart failure, alleviation of 
symptoms, or a decrease in heart rate to less 
than 50 beats per minute. In some patients, one 
may have to stop the drug because of broncho-
spasm. 
Metoprolol was recently introduced in the 
United States but has been used in Europe for a 
long time. It is quite similar to propranolol but 
has less effect on beta-two receptors It is there-
fore preferable for patients with lung disease. 
Otherwise, the many side effects are similar to 
those of propranolol. One must remember that 
both propranolol and metoprolol are associated 
with rebound angina if the drug is rapidly with-
drawn from patients who have responded. 
Equipotent dosages of propranolol and me-
toprolol are about 40 mg of propranolol and 50 
mg metoprolol and appear to produce the same 
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decrease in heart rate , reduction of angina pec-
toris, reduction of nitroglycerin consumption 
and improvement in exercise tolerance testing . 
In European studies, propranolol and metopro-
lol were given every eight hours, but in the 
United States, administration of propranolol 
every six hours is more common. 
Specific studies with lsord il®, in which the 
drug was continued for up to 5 to 6 months, 
have shown sustained symptomatic relief in 
terms of the decreased frequency of anginal at-
tacks, the number of nitroglycerin tablets used 
by the patient , and improved exercise toler-
ance. Other studies have shown that continued 
administration of lsordil® does not interfere with 
the patient 's usual response to sublingual nitro-
glycerin: it does not blunt hemodynamic effects 
induced by nitroglycerin or the relief of angina 
Similar results have been obtained with long-
term studies of nitroglycerin ointment. One can 
therefore conclude that there is good evidence 
that lsordil® and topical nitroglycerin do cause 
improvement in the patient's symptoms and 
functional status both subjectively and objec-
tively , possibly for several months. However, 
none of these studies answer the question "'will 
they prevent myocardial infarction and sudden 
death?" 
Propranolol and metoprolol have been 
studied in a similar manner. In 1969, 3 patients 
clinically defined as having angina pectoris 
were further subdivided into those having coro-
nary artery disease as judged by coronary arte-
riography (50% occlusion of at least one coro-
nary artery) or a demonstrated transmural 
infarction , and a second group of patients with 
clinical angina but negative coronary arterio-
grams. Successful response to propranolol was 
defined by at least a 50% decrease in in-
cidence of angina, a 50% decrease in the num-
ber of nitroglycerin tablets used , or loss of one 
or more provoking factors of angina . Only 23% 
of patients with c linical angina but without 
proven coronary artery disease responded to 
the drug; the patients with proven coronary ar-
tery disease responded 86% of the time. Thus, 
without employing coronary arteriography one 
could have concluded that propranolol was less 
successful in the treatment of angina pectoris 
than it really is. This study showed that the dose 
of propranolol required for a favorable response 
was 1 60 to 240 mg a day and that the re-
sponse to the drug did not correlate with the 
number of vessels involved or the severity of the 
patient 's pretreatment angina. 
In 1976 another study4 attempted to show 
that the patient 's response to propranolol ap-
peared to affect mortality. Despite some loop-
holes the study did clearly indicate that patients 
who failed to respond to medical management 
appeared to have a worse prognosis than the 
responders; these nonresponders are therefore 
the patients who are usually referred for sur-
gery. 
Most studies conclude that high doses of 
propranolol clearly decrease the incidence of 
angina and allow the patients to lead more nor-
mal lives. Other evidence has shown that exer-
c ise to lerance a lso improves , although if 
metoprolol and propranolol are used , it is often 
not angina that curtails the patient's activity but 
frequently a fatigue-like syndrome; some stud-
ies have shown that if the patient is maintained 
on a combination of propranolol and isosorbide 
dinitrate, exercise tolerance improves even 
more. It would seem logical that as these two 
drugs affect different determinants of oxygen 
demand , a combination of the two might be 
more effective than either one used singly 
In summary , one can clearly state that the 
medical therapy of angina pectoris is better than 
no therapy at all and that some patients clearly 
do obtain subjective as well as objective im-
provement. However, one still cannot determine 
whether or not there is clear improvement utiliz-
ing medical therapy in terms of mortality relative 
to the natural history of the disease. There are 
also limitations to the use of the drugs and there 
are c learly failures ; these drugs do not halt pro-
gression of the underlying atherosclerotic proc-
ess and therefore do not cure. The choice be-
tween medical or surgical therapy depends on 
many factors which are often defined by angi-
ography, determined by the failure of whatever 
the physician believes to be maximum medical 
therapy, and commonly influenced by the local 
surgeon 's skills. The patient as well as the phy-
sician has a profound influence on whether 
medical or surgical therapy is ultimately used. 
REFERENCES 
1 OBERMAN A, JONES WB, RILEY CP, ET AL : Natural history 
of co rona ry artery d isease Bull NY Acad Med 
48. 1109- 11 25, 1972. 
2. FRICK MH, LUURILA 0 : Double-blind titrated-dose com-
parison of metoprolol and propranolol in the treatment 
of angina pectoris Ann Clin Res 8 385-392, 1976. 
3 AMSTERDAM EA, GORLIN R, WOLFSON S: Evaluation of 
long-term use of propranolol and angina pectoris. JAMA 
21 0 :103- 106, 1969. 
4 WARREN SG, BREWER DL, ORGAIN ES: Long-term pro-
pranolo l therapy for angina pectoris Am J Cardiol 
37 420- 426 , 1976. 
General Review 
JULIAN DG: Diagnosis and management of angina pec-
toris, in Current Problems in Cardiology Yearbook 
Medical Publishers, Inc 2:7, 1977. 
HASTILLO MEDICAL MANAGEMENT OF ANGINA / 33 
The Management of Patients with Premature 
Ventricular Contractions 
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Premature ventricular contractions (PVCs) 
occur frequently in patients with virtually all 
types of cardiac disease and in persons without 
evidence of cardiac disease. Since PVCs and 
advanced grades of PVCs are known to be pre-
dictors for ventricular fibrillation, increased mor-
tality , and sudden death in certain clinical set-
tings, the management of patients with PVCs is 
frequently based on the clinical setting in which 
they occur. For the purpose of this talk we will 
discuss the treatment of PVCs in the following 
three instances: acute myocardial infarction in 
the coronary care unit , post-myocardial in-
farction patients , and persons without any evi-
dence of organic heart disease. 
Acute Myocardial Infarction 
Almost all patients with acute myocardial 
infarction have PVCs during the first few days . 
The frequency of PVCs is greatest in the first 
hours after infarction and decreases gradually 
and progressively during the next several hours 
and days In acute myocardial infarction, Lown 
and co-workers 1 described certain types of 
PVCs that commonly preceded ventricular fibril-
lation. They applied the term "serious ventricu-
lar arrhythmias' ' to the following types of PVCs: 
(1) occurrence at a rate of five or more per 
minute , (2) " R on T" phenomenon, (3) multi-
form PVCs, (4) paired PVCs, and (5) ventricular 
tachycardia. When observed on routine mon-
itoring , these premonitory ventricular arrhyth-
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mias were treated with lidocaine, and Lown and 
associates reported less than a 2% incidence of 
primary cardiac arrest in 300 patients with 
acute myocardial infarction. 2 The detection of 
serious ventricular arrhythmias from the cardiac 
monitor followed by suppression with anti-
arrhythmic drugs is the approach in many coro-
nary care units today 
There are two problems with this ap-
proach. First, the serious ventricular arrhythmias 
appear to be neither very sensitive nor very spe-
cific for the subsequent development of ven-
tricular fibrillation. El-Sherif and associates3 
found that only 11 (58%) of 1 9 patients with an 
acute myocardial infarction who developed ven-
tricular fibrillation had premonitory arrhythmias. 
In the 1 7 patients where ventricular fibrillation 
was preceded by a single PVC, 1 0 had early 
PVCs or " R on T" phenomenon. Of the 430 
patients without ventricular fibrillation in this se-
ries , 236 (55%) had premonitory ventricular ar-
rhythmias and 1 94 (45%) did not. A second 
study4 reported similar findings 
The second problem is the adequacy of 
the detection system for arrhythmias as it is rou-
tinely employed in the coronary care unit. We 
compared the recognition of arrhythmias in 31 
patients with acute myocardial infarction by the 
nurses and by rate-alarm signals in the coronary 
care unit with a continuous five-day tape record-
ing that was subsequently processed through 
an automated Hewlett-Packard arrhythmia de-
tection system. The Hewlett-Packard system 
printed out all arrhythmias for verification and 
quantification by the investigators. 5 The obser-
vation of conventional monitors by coronary 
care unit personnel in conjunction with rate-
alarm systems resulted in an inadequate detec-
tion rate of PVCs and serious ventricular ar-
rhythmias compared to the subsequent analysis 
of the tape recording (Table). In addition, there 
was a considerable time delay between the ini-
tial occurrence of PVCs and serious ventricular 
arrhythmias on the tape and their recognition by 
coronary care unit personnel Arrhythmia recog-
nition in coronary care units has improved and 
computer systems are available which can be 
used on line to improve the detection rate for 
PVCs; however, most coronary care units con-
tinue to rely on trained personnel for arrhythmia 
recognition. 
Since there is such a high incidence of 
PVCs in patients with acute myocardial in-
farction , the prophylactic administration of anti-
arrhythmic drugs has been evaluated exten-
s ively. Initially quinidine ,6 procainamide, 7 
lidocaine, 8 and phenytoin 9 were reported to re-
duce significantly PVCs and serious ventricular 
arrhythmias , without reducing mortality The pa-
tients in these studies were always a good-risk 
population with a low mortality in the control 
groups. In addition , when arrhythmias were rec-
ognized in the control groups, they were 
treated. More recently, Lie and co-workers 1 0 in 
a double-blind randomized study demonstrated 
that lidocaine given prophylactically as an initial 
1 00 mg bolus followed by an infusion rate of 
three mg/min significantly decreased the in-
cidence of primary ventricular fibrillation , but 
mortality was not effected since all but one pa-
tient with ventricular fibrillation was resuscitated. 
The frequency of side effects at this infusion 
rate was 1 5% and was higher in the 60- to 70-
year age group than in patients below the age 
of 60. 
Since the PVC predictors for ventricular 
fibrillation are less reliable than indicated in ini-
tial reports, and PVC detection by conventional 
monitoring in the coronary care unit is not opti-
mal, there is evidence available to recommend 
the prophylactic administration of lidocaine to 
patients during the first 48 to 72 hours of an 
acute myocardial infarction for the prevention of 
primary ventricular fibrillation. Patients with evi-
dence of heart block, cardiogenic shock, se-
vere congestive heart failure , and sinus brady-
cardia (below the rate of 50) probably should be 
excluded from this recommendation. Since pa-
tients above the age of 70 apparently have a 
low incidence of primary ventricular fibrillation in 
the coronary care unit and a higher incidence of 
adverse reactions to lidocaine , they also should 
probably be excluded from this recommenda-
tion. 
The dosage of intravenous lidocaine used 
for prophylaxis is important. When a loading 
dose of 50 to 1 00 mg followed by a 2 mg/min 
infusion rate is used , there is an initial period of 
six to seven hours when plasma levels are sub-
optimal. 11 In an effort to avoid 't,/lis dip in plasma 
levels it is necessary to give about 200 mg of 
lidocaine in the first 20 minutes. 1 2 There are 
several ways to give this loading dose: (1) 1 00 
mg given twice at ten-minute intervals; (2) 50 
mg given four times at five-minute intervals; (3) 
infusion of 20 mg / min for ten minutes; and (4) 
1 00 mg bolus followed by infusion of 6 to 7 
mg / min for 1 5 minutes. I prefer the last method 
followed by the continuous administration at an 
infusion rate of 2 to 4 mg / min , preferably 3 
mg / min In patients with shock , congestive 
heart failure , or hepatocellular disease, the 
loading dose and infusion rates should be de-
creased by about 50%. This may also apply to 
patients over the age of 7 0 . If PVCs occur , the 
plasma concentration of lidocaine can be raised 
rapidly with a 25 to 50 mg bolus and an in-
crease in the infusion rate. There is some evi-
dence that the plasma half-life of lidocaine in-
creases by a factor of about two after 24 hours 
TABLE 
Premature Ventricular Contractions 
Serious Ventricular Arrhythmias 
Premature Atrial Contractions 
Ventricular Fibrillat ion, Atrial 
Fibrillation, Asystole, Complete 
Heart Block, Junct ional Tachycardia 
Arrhythmia Recognition in Acute Infarction 
(3 1 Patients) 
CONVENTIONAL 
M ONITOR 
64 .5% 
16% 
45.2% 
Identical 
AUTOMATED 
D ETECTION 
SYSTEM 
100% 
93 5% 
96 .8% 
Identical 
TIME D ELAY 
IN RECOGNITION 
(HOURS) 
18 
10 
23 
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in patients with acute myocardial infarction, thus 
the infusion rate may have to be decreased at 
this time. 13 
Post-Myocardial Infarction 
In patients with a previous myocardial in-
farction many studies have reported an in-
creased mortality and /or an increased fre-
quency of sudden death in patients with PVCs 
or advanced grades of PVCs. 14 - 18 Although 
there is some variabliity in the reported studies, 
the increased mortality appears to be true for 
th e presence of PVCs on a routine elec-
trocardiogram as in the Coronary Drug Proj-
ect , 14 and for an increased frequency of PVCs 
(>1 0 per hour or > 20 per hour) or advanced 
grades of PVCs or both during monitoring stud-
ies. In contrast to these studies, the work of 
Moss and co-workers, 18· 19 has indicated that 
PVCs and advanced grades of PVCs have lim-
ited use in predicting subsequent cardiac 
events and a similar study has been reported by 
de Soyza and associates. 2 0 It is likely that PVCs 
and advanced grades of PVCs will be neither 
sensitive nor specific for the prediction of sub-
sequent mortality in post-myocardial infarction 
patients similar to the findings in patients with 
acute myocardial infarction. There may be two 
exceptions to this. The first exception may be 
those patients with a low-ejection fraction (less 
than 40%) and advanced grades of PVCs who 
have an increased incidence of sudden death 
compared to patients with a low-ejection frac-
tion without advanced grades of PVCs. 2 1 The 
second exception may be those patients who 
develop ventricular arrhythmias with low-level 
exercise tests to a heart rate of 1 30 beats per 
minute or symptoms at three weeks post-
infarction. 22 
There are three controlled clinical trials 
that have been carried out in Europe, evaluating 
the prophylactic administration of beta adrener-
gic-blocking drugs in postinfarction patients 
The fi rst trial, in Sweden, using alprenolol in 
230 patients demonstrated a significant reduc-
tion in sudden death , but not in total mortality or 
recurrent infarction 23 The second study, also in 
Sweden and also using alprenolol, reported a 
significant reduction in sudden death and recur-
rent infarction but not in total mortality. 2 4 A large 
rriulticenter trial in England with practolol dem-
onstrated a significant reduction in cardiac 
death and sudden death, particularly after ante-
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rior infarctions. 25 In this trial the rate of recurrent 
infarction was reduced but was not statistically 
significant. The trial had to be terminated be-
cause of the ocular complications associated 
with long-term practolol administration. Since 
the incidence of recurrent infarction was shown 
to be reduced, the mechanism of the beneficial 
effect of beta adrenergiccblocking drugs may 
not be entirely related to their antiarrhythmic 
properties. In June 1978 a large multicenter 
trial was started in the United States, using pro-
pranolol in post-infarction patients, and the 
Medical College of Virginia is one of the clinical 
centers. 
It is possible that oral antiarrhythmic drugs 
(quinidine, procainamide, disopyramide, pheny-
toin , or propranolol) on a long-term basis may 
be beneficial in postinfarction patients , but the 
results of additional clinical trials with drugs 
available in the United States are needed. At the 
present time postinfarction patients with fre-
quent or advanced grades of PVCs may benefit 
from antiarrhythmic drugs, partic:;u larly when the 
PVCs are associated with a low-ejection frac-
tion , angina pectoris, or a positive exercise test. 
It is essential that patients have a baseline mon-
itoring or exerc ise study (whichever demon-
strated the PVCs) prior to therapy and again af-
ter institution of therapy in conj unction with 
blood levels of the drug , when available, to eval-
uate the effectiveness of the antiarrhythmic 
therapy. It also should be remembered that we 
do not really have a good oral antiarrhythmic 
drug approved for use in the United States. 
Without Organic Heart Disease 
The significance of PVCs in persons with-
out evidence of organic heart disease is less 
clear and can be a difficult probl.em with respect 
to treatment. Hinkle and co-workers reported 
that 62% of middle-aged American men had 
PVCs during a six-hour recording. 2 6 The pres-
ence of PVCs or more than 1 0 PVCs per 1 000 
beats correlated with an increased risk of sud-
den death . In the Tecumseh Study there was a 
significant increase in mortality in persons over 
the age o f 3 0 with PVCs o n an elec-
trocardi og ram com pared to those without 
PVCs. 27 However, in both of these studies there 
was also a correlation between PVCs and the 
presence of coronary artery disease. Thus, 
PVCs appear to be only a marker for coronary 
artery disease in these studies, but are not spe-
cific enough for coronary artery disease to be 
useful in individual patients Fifty percent of 
male medical students had PVCs during a 24-
hour period , but on ly 2% had more than 50 
PVCs during the 24 hours. 28 In persons without 
organic heart disease PVCs are frequently asso-
ciated with fatigue, anxiety , or use of coffee, to-
bacco, tea or alcohol. 2 9 Removal of these fac-
tors will often decrease or eliminate the PVCs. 
In general the use of antiarrh ythmic drugs 
should be avoided in individuals who have 
PVCs without evidence of organic heart dis-
ease. 
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